EP Patent

EP2249859B1 — Treatment of metastatic stage prostate cancer with degarelix

Assigned to Ferring BV · Expires 2014-04-23 · 12y expired

What this patent protects

Patent listed against degarelix-acetate.

Drugs covered by this patent

degarelix-acetate (DEGARELIX ACETATE)

Patent Metadata

Patent number: EP2249859B1
Jurisdiction: EP
Classification: —
Expires: 2014-04-23
Drug substance claim: No
Drug product claim: No
Assignee: Ferring BV
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.